Does the media favor ANVS or CORT?

In the previous week, Corcept Therapeutics had 3 more articles in the media than Annovis Bio. MarketBeat recorded 5 mentions for Corcept Therapeutics and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.11 beat Corcept Therapeutics' score of 0.85 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CORT or ONC?

In the previous week, BeOne Medicines had 6 more articles in the media than Corcept Therapeutics. MarketBeat recorded 11 mentions for BeOne Medicines and 5 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.85 beat BeOne Medicines' score of 0.57 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CORT or RPRX?

In the previous week, Corcept Therapeutics had 1 more articles in the media than Royalty Pharma. MarketBeat recorded 5 mentions for Corcept Therapeutics and 4 mentions for Royalty Pharma. Corcept Therapeutics' average media sentiment score of 0.85 beat Royalty Pharma's score of 0.68 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Royalty Pharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZTS or CORT?

In the previous week, Zoetis had 3 more articles in the media than Corcept Therapeutics. MarketBeat recorded 8 mentions for Zoetis and 5 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.85 beat Zoetis' score of 0.43 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Corcept Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Corcept Therapeutics (CORT) Competitors

$116.23 +2.20 (+1.93%)

Closing price 04:00 PM Eastern

Extended Trading

$117.29 +1.06 (+0.91%)

As of 05:50 PM Eastern

Compare

CORT vs. ANVS, TEVA, ONC, RPRX, and ZTS

Should you buy Corcept Therapeutics stock or one of its competitors? Corcept Therapeutics's main competitors and comparable companies include Annovis Bio (ANVS), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), and Zoetis (ZTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Corcept Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Corcept Therapeutics has a net margin of 6.52% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
Corcept Therapeutics	6.52%	8.26%	6.45%

Annovis Bio presently has a consensus price target of $12.00, indicating a potential upside of 930.04%. Corcept Therapeutics has a consensus price target of $138.17, indicating a potential upside of 18.79%. Given Annovis Bio's higher possible upside, analysts clearly believe Annovis Bio is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Corcept Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Corcept Therapeutics had 3 more articles in the media than Annovis Bio. MarketBeat recorded 5 mentions for Corcept Therapeutics and 2 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 1.11 beat Corcept Therapeutics' score of 0.85 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 15.9% of Annovis Bio shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
Corcept Therapeutics	$761.41M	16.51	$99.65M	$0.42	276.94

Annovis Bio has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Summary

Corcept Therapeutics beats Annovis Bio on 13 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Corcept Therapeutics (NASDAQ:CORT) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Corcept Therapeutics has a net margin of 6.52% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Corcept Therapeutics	6.52%	8.26%	6.45%

Teva Pharmaceutical Industries currently has a consensus target price of $44.67, indicating a potential upside of 13.25%. Corcept Therapeutics has a consensus target price of $138.17, indicating a potential upside of 18.79%. Given Corcept Therapeutics' higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92
Corcept Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Teva Pharmaceutical Industries has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 19 more articles in the media than Corcept Therapeutics. MarketBeat recorded 24 mentions for Teva Pharmaceutical Industries and 5 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.85 beat Teva Pharmaceutical Industries' score of 0.59 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	7 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than Corcept Therapeutics. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.66	$1.41B	$0.60	65.73
Corcept Therapeutics	$761.41M	16.51	$99.65M	$0.42	276.94

Summary

Corcept Therapeutics beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to BeOne Medicines?

Corcept Therapeutics (NASDAQ:CORT) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BeOne Medicines has higher revenue and earnings than Corcept Therapeutics. BeOne Medicines is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.51	$99.65M	$0.42	276.94
BeOne Medicines	$5.34B	7.26	$286.93M	$5.68	62.22

Corcept Therapeutics currently has a consensus target price of $138.17, indicating a potential upside of 18.79%. BeOne Medicines has a consensus target price of $404.14, indicating a potential upside of 14.35%. Given Corcept Therapeutics' higher possible upside, research analysts plainly believe Corcept Therapeutics is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
BeOne Medicines	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.06

BeOne Medicines has a net margin of 10.70% compared to Corcept Therapeutics' net margin of 6.52%. BeOne Medicines' return on equity of 14.23% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
BeOne Medicines	10.70%	14.23%	7.82%

In the previous week, BeOne Medicines had 6 more articles in the media than Corcept Therapeutics. MarketBeat recorded 11 mentions for BeOne Medicines and 5 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.85 beat BeOne Medicines' score of 0.57 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Summary

BeOne Medicines beats Corcept Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Royalty Pharma?

Corcept Therapeutics (NASDAQ:CORT) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.51	$99.65M	$0.42	276.94
Royalty Pharma	$2.38B	13.90	$770.95M	$1.45	39.65

Corcept Therapeutics has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Royalty Pharma has a net margin of 32.14% compared to Corcept Therapeutics' net margin of 6.52%. Royalty Pharma's return on equity of 30.01% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Royalty Pharma	32.14%	30.01%	14.91%

In the previous week, Corcept Therapeutics had 1 more articles in the media than Royalty Pharma. MarketBeat recorded 5 mentions for Corcept Therapeutics and 4 mentions for Royalty Pharma. Corcept Therapeutics' average media sentiment score of 0.85 beat Royalty Pharma's score of 0.68 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics presently has a consensus price target of $138.17, indicating a potential upside of 18.79%. Royalty Pharma has a consensus price target of $61.29, indicating a potential upside of 6.59%. Given Corcept Therapeutics' higher possible upside, equities analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Royalty Pharma beats Corcept Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Zoetis?

Zoetis (NYSE:ZTS) and Corcept Therapeutics (NASDAQ:CORT) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Zoetis currently has a consensus target price of $101.08, suggesting a potential upside of 45.13%. Corcept Therapeutics has a consensus target price of $138.17, suggesting a potential upside of 18.79%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Corcept Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Zoetis has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.04	$2.67B	$6.07	11.47
Corcept Therapeutics	$761.41M	16.51	$99.65M	$0.42	276.94

Zoetis has a net margin of 27.49% compared to Corcept Therapeutics' net margin of 6.52%. Zoetis' return on equity of 74.89% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
Corcept Therapeutics	6.52%	8.26%	6.45%

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Zoetis had 3 more articles in the media than Corcept Therapeutics. MarketBeat recorded 8 mentions for Zoetis and 5 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.85 beat Zoetis' score of 0.43 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Corcept Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zoetis beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Corcept Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CORT vs. The Competition

Export

Metric	Corcept Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.56B	$12.21B	$7.10B	$13.24B
Dividend Yield	N/A	2.63%	2.53%	15.88%
P/E Ratio	276.74	797.15	274.33	26.05
Price / Sales	16.50	751.67	601.06	89.40
Price / Cash	127.64	81.79	77.38	51.25
Price / Book	18.87	10.47	10.92	6.31
Net Income	$99.65M	$2.83B	$3.50B	$361.43M
7 Day Performance	0.11%	-1.66%	-2.11%	-1.67%
1 Month Performance	5.25%	-5.78%	-6.34%	-3.94%
1 Year Performance	35.97%	-3.81%	8.81%	2.77%

Corcept Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CORT Corcept Therapeutics	3.7512 of 5 stars	$116.23 +1.9%	$138.17 +18.9%	+35.3%	$12.56B	$761.41M	276.74	730
ANVS Annovis Bio	2.8928 of 5 stars	$1.28 +1.2%	$12.00 +841.2%	-45.7%	$53.78M	N/A	N/A	7	Gap Up
TEVA Teva Pharmaceutical Industries	3.6694 of 5 stars	$39.10 -1.1%	$43.73 +11.8%	+96.4%	$46.05B	$17.26B	65.17	33,950	Trending News Analyst Forecast
ONC BeOne Medicines	3.6589 of 5 stars	$365.00 -0.8%	$402.71 +10.3%	+7.0%	$40.41B	$6.13B	64.26	12,000	Trending News Analyst Forecast Insider Trade Gap Up
RPRX Royalty Pharma	4.3585 of 5 stars	$57.65 -1.5%	$61.29 +6.3%	+58.7%	$33.65B	$2.54B	39.76	100	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CORT) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, TEVA, ONC, RPRX, and ZTS

How does Corcept Therapeutics compare to Annovis Bio?

Summary

How does Corcept Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Corcept Therapeutics compare to BeOne Medicines?

Summary

How does Corcept Therapeutics compare to Royalty Pharma?

Summary

How does Corcept Therapeutics compare to Zoetis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, TEVA, ONC, RPRX, and ZTS

How does Corcept Therapeutics compare to Annovis Bio?

Is ANVS or CORT more profitable?

Do analysts recommend ANVS or CORT?

Does the media favor ANVS or CORT?

Do institutionals and insiders believe in ANVS or CORT?

Which has better earnings and valuation, ANVS or CORT?

Which has more risk & volatility, ANVS or CORT?

Summary

How does Corcept Therapeutics compare to Teva Pharmaceutical Industries?

Is TEVA or CORT more profitable?

Do analysts prefer TEVA or CORT?

Which has more volatility & risk, TEVA or CORT?

Does the media favor TEVA or CORT?

Do institutionals & insiders believe in TEVA or CORT?

Which has higher earnings & valuation, TEVA or CORT?

Summary

How does Corcept Therapeutics compare to BeOne Medicines?

Do insiders and institutionals have more ownership in CORT or ONC?

Which has stronger earnings and valuation, CORT or ONC?

Do analysts prefer CORT or ONC?

Is CORT or ONC more profitable?

Does the media refer more to CORT or ONC?

Which has more risk & volatility, CORT or ONC?

Summary

How does Corcept Therapeutics compare to Royalty Pharma?

Which has preferable earnings & valuation, CORT or RPRX?

Which has more risk & volatility, CORT or RPRX?

Do insiders & institutionals believe in CORT or RPRX?

Is CORT or RPRX more profitable?

Does the media prefer CORT or RPRX?

Do analysts recommend CORT or RPRX?

Summary

How does Corcept Therapeutics compare to Zoetis?

Do analysts rate ZTS or CORT?

Which has more volatility & risk, ZTS or CORT?

Which has preferable valuation and earnings, ZTS or CORT?

Is ZTS or CORT more profitable?

Do insiders & institutionals hold more shares of ZTS or CORT?

Does the media favor ZTS or CORT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools